eligibility_summary
Inclusion: Adults (≥18) with untreated CLL/SLL per IWCLL 2018, measurable disease, need for therapy, ECOG 0–2, adequate organs, able to take oral meds, consent. Exclusion: Richter’s/CNS disease, bleeding disorder, recent stroke/ICH, major cardiac disease (arrhythmia, NYHA III/IV, LVEF<40%), other cancer life expectancy <2y, investigational agents, recent immunosuppression, live vaccine, major surgery, or IV infection, HIV/HTLV/HBV/HCV/CMV, pregnancy/lactation, malabsorption, uncontrolled autoimmune cytopenia, serious comorbidity.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Drugs/interventions: • Pirtobrutinib – oral, small‑molecule, noncovalent (reversible) Bruton’s tyrosine kinase (BTK) inhibitor. Mechanism: blocks BTK within the B‑cell receptor (BCR) pathway (active against WT and C481‑mutant BTK), reducing malignant B‑cell survival, proliferation, and trafficking. • Obinutuzumab – IV, type II, glycoengineered humanized anti‑CD20 monoclonal antibody. Mechanism: binds CD20 on B cells, inducing direct cell death and strong Fc‑mediated ADCC/ADCP, leading to B‑cell depletion. Cells/pathways targeted: CLL/SLL malignant B‑lymphocytes, BCR/BTK signaling (BTK→PLCγ2, NF‑κB, PI3K/AKT), immune effector pathways via NK cells/macrophages through Fcγ engagement.